Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446784 · ClinicalTrials.gov registry record · Phase 1
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00446784 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT00446784, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
Interventions
- DRUG Methotrexate
- DRUG CE-224,535
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446784
The ClinicalTrials.gov registry entry for NCT00446784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methotrexate is the first listed.
NCT00446784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446784 about?
NCT00446784 is a clinical study titled "Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis". CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate
What is the current status of trial NCT00446784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00446784?
The interventions under investigation include: Methotrexate (DRUG), CE-224,535 (DRUG).
Who is sponsoring clinical trial NCT00446784?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.